Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- Vertex expects 2026 total revenue of $12.95 billion to $13.1 billion, representing 8%-9% growth. - Vertex reiterates 2026 total revenue guidance of $12.95 billion to $13.1 billion, reflecting 8%-9% growth year-over-year.
From Vertex Pharmaceuticals Incorporated's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Vertex expects 2026 total revenue of $12.95 billion to $13.1 billion, representing 8%-9% growth.
- They anticipate JOURNAVX to more than triple prescriptions from 2025 levels (550,000), with revenue growth exceeding prescription growth.
- JOURNAVX revenue in Q1 was $29 million, with strong growth drivers including field force expansion and payer coverage (240 million lives covered).
- CASGEVY revenue ($43 million in Q1) is expected to contribute meaningfully to $500 million+ revenue from non-CF products, with strong visibility for 2026.
- ALYFTREK continues to grow with label expansions, treatment of younger patients, and geographic rollout; has surpassed $1 billion cumulative revenue.
2 more points from Vertex Pharmaceuticals Incorporated's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Vertex Pharmaceuticals Incorporated said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Vertex is investing in manufacturing network and process development for various products, contributing to their non-GAAP operating expenses.
- Continued investment in late-stage clinical pipeline and commercial infrastructure for new launches and revenue diversification is planned.
- While specific capital expenditures (capex) amounts are not detailed, the company emphasizes targeted investments as part of operational expenses.
- Vertex maintains a strong cash position ($13 billion) and demonstrates commitment to innovation investment alongside share repurchases.
2 more points from Vertex Pharmaceuticals Incorporated's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Vertex Pharmaceuticals Incorporated said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- No explicit mention of a current or expected order book or pending orders in the provided pages.
- The company highlights strong sales performance with over 1 million prescriptions written for JOURNAVX and more than 500 people initiating CASGEVY treatment.
- ALYFTREK has exceeded $1 billion in cumulative revenue.
- The company is on track to more than triple JOURNAVX prescriptions compared to 2025.
- Coverage for JOURNAVX has expanded to 240 million lives, with ongoing progress in securing further coverage.
2 more points from Vertex Pharmaceuticals Incorporated's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Vertex Pharmaceuticals Incorporated and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Vertex Pharmaceuticals Incorporated Q2 FY26 results?
- Vertex expects 2026 total revenue of $12.95 billion to $13.1 billion, representing 8%-9% growth. - Vertex reiterates 2026 total revenue guidance of $12.95 billion to $13.1 billion, reflecting 8%-9% growth year-over-year.
What is Vertex Pharmaceuticals Incorporated share price analysis?
Vertex Pharmaceuticals Incorporated currently shows a neutral. The stock trades at a P/E of 25.8 with a market cap of $113,697. Investors should review the full earnings analysis for detailed insights.
Is Vertex Pharmaceuticals Incorporated planning capital expenditure?
- Vertex is investing in manufacturing network and process development for various products, contributing to their non-GAAP operating expenses.
Keep Vertex Pharmaceuticals Incorporated on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.